Organs Without Blood Vessels

Over 100,000 Americans are on the organ transplant waiting list, and 17 die daily waiting. 3D bioprinting — fabricating organs layer by layer using living cells and biomaterial scaffolds — offers a theoretical path to unlimited, patient-matched organs, but no bioprinted organ has achieved the structural complexity, cell density, vascularization, or immune compatibility required for clinical transplantation. The core technical barrier is vascularization: solid organs (kidney, liver, heart) require dense networks of blood vessels down to the capillary scale (~5–10 μm) to supply oxygen and nutrients to every cell. Current bioprinters cannot fabricate vasculature at this resolution within the timeframe required to keep printed cells alive.

The organ shortage is a permanent structural crisis — demand grows 5% annually while supply is flat. Approximately 6,000 Americans die each year waiting for a transplant. Even successful transplants require lifelong immunosuppressive drugs that increase infection and cancer risk. A bioprinted organ made from a patient's own cells (or from a universal donor cell bank) could eliminate both the supply shortage and the need for immunosuppression. The global organ transplant market exceeds $15 billion annually; the unmet need is several times larger.

Bioprinting thin tissues (skin grafts, corneal patches, cartilage patches) has reached clinical translation because these tissues can survive by diffusion without internal vasculature. But solid organs require perfusable vascular networks at multiple scales — arteries, arterioles, capillaries — integrated with organ-specific parenchymal tissue. Current extrusion-based bioprinters achieve ~200 μm resolution, far too coarse for capillaries. Sacrificial printing (printing a dissolvable material to create channels, then seeding with endothelial cells) can create larger vessels but cannot replicate the hierarchical branching geometry of native vascular trees. Cell density in bioprinted constructs is typically 10–100× lower than native tissue, and printed cells often lose their differentiated function during the printing process due to shear stress, UV exposure, or lack of appropriate extracellular matrix signals. Xenotransplantation (genetically modified pig organs) is advancing as an alternative but faces its own immunological and infectious disease barriers.

Three parallel advances would converge: (1) multi-scale bioprinting technologies that can fabricate vasculature from the artery scale (~mm) down to capillary scale (~μm) within a single construct, in a timeframe that keeps cells viable; (2) bioink formulations and culture protocols that maintain cell viability, density, and differentiated function during and after printing; (3) immune engineering approaches — using patient-derived iPSCs or gene-edited universal donor cells — that produce organs accepted by the recipient's immune system without immunosuppression. The ARPA-H PRINT program targets kidney, heart, and liver as the three highest-need organs.

A student team could develop and characterize a novel bioink formulation optimized for a specific cell type (e.g., hepatocytes for liver, cardiomyocytes for heart), measuring cell viability, function retention, and printability under different printing conditions. A more systems-oriented team could design a perfusion bioreactor for maturing small-scale bioprinted tissue constructs, measuring how perfusion rate affects cell survival and organization. Relevant disciplines: biomedical engineering, tissue engineering, materials science, cell biology, mechanical engineering.